Approval
The FDA approved Foundayo on April 1, 2026, for adults with obesity, or with overweight and at least one weight-related condition, used with a reduced-calorie diet and more physical activity. It was the second GLP-1 pill approved for weight management, after the Wegovy pill in December 2025.
Foundayo was the first new molecular entity approved under the FDA Commissioner's National Priority Voucher pilot program, which speeds up review of selected medicines, and the program's fifth approval overall. The FDA approved it 50 days after filing.
Mechanism of action
Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist. Most GLP-1 medicines, such as semaglutide, are peptides, which are protein-like chains that the stomach breaks down. Orforglipron is not a peptide, so it does not need an absorption enhancer.
For this reason, the Foundayo label allows the tablet to be taken once a day at any time, with or without food. Semaglutide tablets, by contrast, carry empty-stomach rules.
Clinical evidence
The approval was based on the ATTAIN phase 3 program. In ATTAIN-1, adults with obesity on the highest orforglipron dose studied lost 11.2% of their body weight on average after 72 weeks, vs. 2.1% on placebo. The trial used capsules, and the tablet strengths on the label differ in mg from the trial doses.
Forms, doses and side effects
Foundayo tablets come in six strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg. The label starts at the lowest dose and raises it in steps of at least 30 days, a process called titration.
The most common side effects are stomach and gut effects such as nausea, diarrhea, vomiting and constipation. Like other GLP-1 medicines, the label carries a boxed warning about thyroid C-cell tumors. The label also limits the dose when Foundayo is used with certain drugs that slow its breakdown.
For how Foundayo compares with weekly injections, see our pill vs. shot comparison.
See also
References
- FDA approves first new molecular entity under National Priority Voucher program, FDA press release, April 1, 2026. fda.gov
- Foundayo (orforglipron) tablets, prescribing information, DailyMed 2026. dailymed.nlm.nih.gov
- Wharton et al., NEJM 2025;393:1796-1806 (ATTAIN-1). pubmed.ncbi.nlm.nih.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.